Sharon Fenick
110 IP cases indexed. Covers patent matters.
Cases Presided Over
110 cases indexed | Page 1 of 4
Samsung Electronics Co., Ltd. et al. v.Hannibal IP LLC
Samsung Electronics and Hannibal IP entered a settlement that led to the joint termination of IPR2025-01189 concerning patent 11,368,911. The Board granted the motion and kept the settlement agreement confidential.
Samsung Electronics Co., Ltd. et al. v.Hannibal IP LLC
Samsung Electronics and Hannibal IP entered a settlement that terminated the IPR on patent 11,272,535. The Board granted the joint motion under 35 U.S.C. §317 and kept the settlement confidential.
WHOOP, Inc. v.Omni MedSci, Inc.
In a Final Written Decision, the PTAB held that WHOOP proved 12 of the 23 challenged claims of Omni MedSci’s wearable physiological‑monitoring patent unpatentable, while the remaining claims were left intact.
WHOOP, Inc. v.Omni MedSci, Inc.
Apple’s IPR against Omni MedSci’s wearable physiological monitoring patent resulted in the Board finding all challenged claims unpatentable as obvious over Lisogurski, Carlson, and Mannheimer references.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB, on remand, affirmed that all 23 claims of Omni MedSci’s wearable pulse‑oximeter patent are unpatentable. The Board relied on obviousness over a combination of prior‑art references and upheld the claim construction of “identify an object.”
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB held that WHOOP proved unpatentability of 12 of the 23 claims of Omni MedSci’s wearable physiological‑measurement patent, while the remaining 11 claims were left intact. The decision hinged on obviousness over a combination of prior‑art references covering optical sensing, modulation, and AI‑driven analysis.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB held that WHOOP’s challenge succeeded, finding all of the asserted claims of Omni MedSci’s ‘533 patent unpatentable as obvious over Lisogurski, Carlson, and Mannheimer prior art.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB held that all challenged claims of the ’533 wearable physiological measurement patent were unpatentable as obvious over Lisogurski, Carlson, and Mannheimer references.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB held that WHOOP’s challenge to Omni MedSci’s 9,651,533 patent failed; all asserted claims were found obvious over Lisogurski, Carlson, and Mannheimer under §103(a).
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB found that WHOOP proved unpatentability of 12 of the 23 claims of Omni MedSci’s wearable physiological monitoring patent, while the remaining 11 claims were left intact. The decision hinged on obviousness over a combination of prior‑art references.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB affirmed the construction of “identify an object” and held that all 23 claims of WHOOP’s wearable health‑monitoring patent are obvious over a combination of prior‑art references, rendering them unpatentable.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB remand decision held that all 23 claims of Omni MedSci’s wearable pulse‑oximetry patent are unpatentable, applying 35 U.S.C. § 103 obviousness over multiple prior‑art references.
WHOOP, Inc. v.Omni MedSci, Inc.
The PTAB held that WHOOP proved the obviousness of 12 of the 23 claims of Omni MedSci’s wearable physiological monitoring patent, while the remaining claims were not shown unpatentable.
WHOOP, Inc. v.Omni MedSci, Inc.
Apple’s IPR against WHOOP resulted in the Board finding all 23 claims of the wearable health‑monitoring patent unpatentable under obviousness. The decision affirmed the petitioner’s claim construction and rejected the patent owner’s arguments.
Samsung Electronics Co., Ltd. et al. v.Hannibal IP LLC
Samsung and Hannibal IP entered a settlement that led to the joint termination of IPR2025-01187 concerning U.S. Patent 11,057,896. The Board granted the motion and ordered the settlement agreement to be kept confidential.
Samsung Electronics Co., Ltd. et al. v.Hannibal IP LLC
Samsung and Hannibal IP entered a settlement, filing a joint motion that led the PTAB to terminate the IPR challenging patent 11,641,661. The Board granted confidentiality for the settlement agreement.
Google LLC v.Valtrus Innovations Limited et al.
The PTAB held that Google’s challenge to Valtrus’s 7,748,005 patent succeeded, finding all twenty claims unpatentable for lack of written‑description support and obviousness over the McCarthy application and Gien micro‑kernel reference.
Google LLC v.Valtrus Innovations Limited et al.
The PTAB held that Google proved all 21 claims of Valtrus’s ’454 patent are obvious over Colby, Eilert, and Jindal, rendering the entire patent unpatentable.
Google LLC v.Valtrus Innovations Limited et al.
Google’s IPR against Valtrus’s 6,728,704 B2 patent was decided with all 23 challenged claims upheld. The Board found the prior‑art Bushee not anticipatory and rejected obviousness arguments over Voorhees, Tso, and Koppel.
Google LLC v.Valtrus Innovations Limited et al.
The PTAB held that Google’s obviousness challenge succeeded, finding all 19 claims of Valtrus’s ’764 patent unpatentable over the Li and Edlund prior‑art references. The decision also denied Google’s motion to exclude exhibits and granted motions to seal.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple succeeded in invalidating Omni MedSci's wearable physiological measurement patent, with the PTAB finding all challenged claims obvious over prior art.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci’s wearable health‑monitoring patent, finding claims 1, 2, 7 and 15‑23 unpatentable while leaving claims 3‑6 and 8‑14 intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR of Omni MedSci’s 9,651,533 patent was decided with all challenged claims found unpatentable under §103, based on obviousness over Lisogurski, Carlson, and Mannheimer prior art.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s ‘299 patent was decided with all challenged claims (7, 10‑14) found unpatentable as obvious over Lisogurski, Carlson, Mannheimer, and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) secured a partial victory over Omni MedSci's wearable health‑monitoring patent, finding 12 of the 23 claims unpatentable while leaving 11 claims intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple successfully invalidated Omni MedSci’s wearable pulse‑oximeter patent in a final PTAB decision, finding all 23 claims unpatentable for obviousness. The Board affirmed claim constructions and applied the petitioner’s alternative argument on the combination of prior‑art references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple successfully challenged Omni MedSci’s wearable health‑monitoring patent. The PTAB affirmed the claim construction and held all 23 claims obvious over prior art. No further briefing was authorized.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed in IPR2020‑00175, with the PTAB finding all challenged claims of the ’299 wearable physiological‑monitoring patent unpatentable as obvious over Lisogurski, Carlson, Mannheimer and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) prevailed on 12 of the 23 challenged claims of Omni MedSci’s wearable physiological monitoring patent, finding them obvious over multiple prior‑art references. The remaining claims were left unpatentable pending further proof.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Apple’s wearable physiological measurement claims were obvious over prior‑art pulse‑oximetry references, rendering all challenged claims unpatentable. The decision relied on Lisogurski, Carlson, and Mannheimer teachings.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.